These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
307 related articles for article (PubMed ID: 28817737)
1. Myc mediates cancer stem-like cells and EMT changes in triple negative breast cancers cells. Yin S; Cheryan VT; Xu L; Rishi AK; Reddy KB PLoS One; 2017; 12(8):e0183578. PubMed ID: 28817737 [TBL] [Abstract][Full Text] [Related]
2. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer. Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991 [TBL] [Abstract][Full Text] [Related]
3. Inhibiting epidermal growth factor receptor signalling potentiates mesenchymal-epithelial transition of breast cancer stem cells and their responsiveness to anticancer drugs. Manupati K; Dhoke NR; Debnath T; Yeeravalli R; Guguloth K; Saeidpour S; De UC; Debnath S; Das A FEBS J; 2017 Jun; 284(12):1830-1854. PubMed ID: 28398698 [TBL] [Abstract][Full Text] [Related]
4. Chemotherapeutic Stress Influences Epithelial-Mesenchymal Transition and Stemness in Cancer Stem Cells of Triple-Negative Breast Cancer. Li X; Strietz J; Bleilevens A; Stickeler E; Maurer J Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936348 [TBL] [Abstract][Full Text] [Related]
5. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus. Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867 [TBL] [Abstract][Full Text] [Related]
6. Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066. Cheng CC; Shi LH; Wang XJ; Wang SX; Wan XQ; Liu SR; Wang YF; Lu Z; Wang LH; Ding Y Int J Oncol; 2018 Jul; 53(1):339-348. PubMed ID: 29750424 [TBL] [Abstract][Full Text] [Related]
7. Low Dose of Paclitaxel Combined with XAV939 Attenuates Metastasis, Angiogenesis and Growth in Breast Cancer by Suppressing Wnt Signaling. Shetti D; Zhang B; Fan C; Mo C; Lee BH; Wei K Cells; 2019 Aug; 8(8):. PubMed ID: 31416135 [TBL] [Abstract][Full Text] [Related]
8. Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer. Liu J; Chen X; Ward T; Pegram M; Shen K Tumour Biol; 2016 Jul; 37(7):9825-35. PubMed ID: 26810188 [TBL] [Abstract][Full Text] [Related]
9. The natural compound Jatrophone interferes with Wnt/β-catenin signaling and inhibits proliferation and EMT in human triple-negative breast cancer. Fatima I; El-Ayachi I; Taotao L; Lillo MA; Krutilina RI; Seagroves TN; Radaszkiewicz TW; Hutnan M; Bryja V; Krum SA; Rivas F; Miranda-Carboni GA PLoS One; 2017; 12(12):e0189864. PubMed ID: 29281678 [TBL] [Abstract][Full Text] [Related]
11. Overexpression of SERPINA3 promotes tumor invasion and migration, epithelial-mesenchymal-transition in triple-negative breast cancer cells. Zhang Y; Tian J; Qu C; Peng Y; Lei J; Li K; Zong B; Sun L; Liu S Breast Cancer; 2021 Jul; 28(4):859-873. PubMed ID: 33569740 [TBL] [Abstract][Full Text] [Related]
12. Tetrandrine Inhibits Cancer Stem Cell Characteristics and Epithelial to Mesenchymal Transition in Triple-Negative Breast Cancer via SOD1/ROS Signaling Pathway. Liu T; Li K; Zhang Z; Peng J; Yang J; Law BYK; Liu X; Li W Am J Chin Med; 2023; 51(2):425-444. PubMed ID: 36692485 [TBL] [Abstract][Full Text] [Related]
13. TGF-β plays a vital role in triple-negative breast cancer (TNBC) drug-resistance through regulating stemness, EMT and apoptosis. Xu X; Zhang L; He X; Zhang P; Sun C; Xu X; Lu Y; Li F Biochem Biophys Res Commun; 2018 Jul; 502(1):160-165. PubMed ID: 29792857 [TBL] [Abstract][Full Text] [Related]
14. 1-Chromonyl-5-Imidazolylpentadienone Demonstrates Anti-Cancer Action against TNBC and Exhibits Synergism with Paclitaxel. Modi K; Lawson S; Chen G; Tumuluri D; Rekhtman I; Kurtz M; Brailoiu GC; Chen QH; Lakshmikuttyamma A Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32806551 [TBL] [Abstract][Full Text] [Related]
15. Interferon-beta represses cancer stem cell properties in triple-negative breast cancer. Doherty MR; Cheon H; Junk DJ; Vinayak S; Varadan V; Telli ML; Ford JM; Stark GR; Jackson MW Proc Natl Acad Sci U S A; 2017 Dec; 114(52):13792-13797. PubMed ID: 29229854 [TBL] [Abstract][Full Text] [Related]
16. Density Gradient Centrifugation Is an Effective Tool to Isolate Cancer Stem-like Cells from Hypoxic and Normoxia Triple-Negative Breast Cancer Models. Sargiacomo C; Klepinin A Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201646 [TBL] [Abstract][Full Text] [Related]
17. Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells. Koike Y; Ohta Y; Saitoh W; Yamashita T; Kanomata N; Moriya T; Kurebayashi J Breast Cancer; 2017 Sep; 24(5):683-693. PubMed ID: 28144905 [TBL] [Abstract][Full Text] [Related]
18. Isochlorogenic Acid C Reverses Epithelial-Mesenchymal Transition Yu JK; Yue CH; Pan YR; Chiu YW; Liu JY; Lin KI; Lee CJ Anticancer Res; 2018 Apr; 38(4):2127-2135. PubMed ID: 29599331 [TBL] [Abstract][Full Text] [Related]
19. Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance. Hill DP; Harper A; Malcolm J; McAndrews MS; Mockus SM; Patterson SE; Reynolds T; Baker EJ; Bult CJ; Chesler EJ; Blake JA BMC Cancer; 2019 Nov; 19(1):1039. PubMed ID: 31684899 [TBL] [Abstract][Full Text] [Related]
20. Tocilizumab potentiates cisplatin cytotoxicity and targets cancer stem cells in triple-negative breast cancer. Alraouji NN; Al-Mohanna FH; Ghebeh H; Arafah M; Almeer R; Al-Tweigeri T; Aboussekhra A Mol Carcinog; 2020 Sep; 59(9):1041-1051. PubMed ID: 32537818 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]